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ABSTRACT 
Objectives: Pneumococcal, tetanus and influenza vaccinations are recommended 
for patients with Cryopyrin-Associated Periodic Syndromes (CAPS) when treated 
with immunosuppressive medication. The aim of this publication is to report the 
safety of pneumococcal and other vaccinations in CAPS patients.  
Methods: All CAPS patients followed in the β-CONFIDENT (Clinical Outcomes and 
Safety Registry study of Ilaris patients) registry were analysed if they had received a 
vaccination. The β-CONFIDENT registry is a global, long-term, prospective, 
observational registry, capturing and monitoring patients treated with canakinumab. 
Results: 68 CAPS patients had received a total of 159 vaccine injections, 107 
injections against influenza, 19 pneumococcal vaccinations, 12 against 
tetanus/diphtheria antigens and 21 other vaccinations. 14% of injections had elicited 
at least one vaccine reaction. All five vaccine related serious adverse events were 
associated with pneumococcal vaccination. Vaccine reactions were observed in 70% 
of pneumococcal vaccinations, compared to 7% in influenza and 17% in 
tetanus/diphtheria vaccinations. The odds ratios to react to the pneumococcal 
vaccines compared to influenza and tetanus/diphtheria vaccines were 31.0 (95%CI8-
119) and 10.8 (95%CI 2-74). Vaccine reactions after pneumococcal vaccinations 
were more severe and lasted significantly longer (up to 3 weeks) compared to other 
vaccinations. In two patients, pneumococcal vaccination also elicited symptoms 
consistent with systemic inflammation due to CAPS reactivation. 
Conclusion: Pneumococcal vaccines, unlike other vaccines, frequently trigger 
severe local and systemic inflammation in CAPS patients. Clinicians must balance 
potential benefits of pneumococcal immunisation against safety concerns. The 13-
valent pneumococcal conjugate vaccine might be favourable over the polysaccharide 
vaccine in CAPS patients. 
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KEY MESSAGES 
 In cryopyrin-associated periodic syndromes patients, pneumococcal vaccines unlike 
other vaccinations frequently induced local inflammation. 
In cryopyrin-associated periodic syndromes, pneumococcal vaccines reactions  were 
more severe, longer-lasting and at times systemic. 
 
INTRODUCTION 
Cryopyrin-Associated Periodic Syndromes (CAPS), specifically Familial Cold 
Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), and Neonatal 
Onset Multisystem Inflammatory Disease (NOMID) are autoinflammatory periodic 
fever syndromes caused by mutations of the NLRP3 gene which elicit a constitutive 
activation of the NLRP3 inflammasome and enhance the synthesis of active IL-1β 
after the detection of danger signals by toll-like receptors (TLR) [1,2]. Canakinumab, 
a human IgG1/k monoclonal antibody that selectively blocks human IL-1β has been 
licensed for the treatment of CAPS [3].  
Patients with CAPS, like other patients with immune related disorders on 
immunosuppressive treatments, may have an increased susceptibility to 
pneumococcal pneumonia [4] which even in the general population represents a 
significant cause of morbidity and mortality [5,6].  
The European League Against Rheumatism (EULAR) and the Advisory Committee 
on Immunisation Practices to the Center for Disease Control and Prevention (CDC) 
therefore recommend pneumococcal vaccination, tetanus and influenza vaccines, 
among other immunisations in patients with periodic fever syndromes treated with 
immunosuppressive medication [5,7].  
Our early recognition of unusually severe local and/or systemic inflammatory adverse 
reactions led us to publish information in a case series of seven CAPS patients, 
consecutively vaccinated with pneumococcal vaccines [8]. Six of the seven patients 
reported in the case series are also included in this analysis as they were followed in 
the β-CONFIDENT (Clinical Outcomes and Safety Registry study of Ilaris patients) 
registry, a long-term prospective observational study of patients treated with 
canakinumab. Following up on the findings of the case series [8], we prospectively 
 investigated the safety of pneumococcal and other vaccines within the entire β-
CONFIDENT registry.  
 
METHODS 
Study population and design 
This study analysed the vaccination safety data of the β-CONFIDENT registry, 
registered in ClinicalTrials.gov (NCT01213641). Each centre contributing to the β-
CONFIDENT registry obtained ethical approval by its local ethics committees or 
institutional review boards; informed consent according to the declaration of Helsinki 
was required from each patient/guardian prior in compliance with local regulations. 
No additional approval was required for this study analyzing the vaccination safety 
data. 
The β-CONFIDENT registry is a global, multicentre, 5 year, prospective, 
observational registry, capturing long-term safety and effectiveness data of adult and 
paediatric patients treated with canakinumab [9]. As this was a non-interventional 
study, patients were treated according to the local prescribing information, and 
routine medical practice. Data collection was in compliance with Good Medical 
Practice and Good Pharmacovigilance Practice. 
Given the observational nature of this study the protocol did not mandate any specific 
schedule of vaccination or follow-up and vaccinations were administered as part of 
regular medical care according to the independent recommendations of treating 
physicians.  
Collection of vaccination data in the registry started in July 2010, and ended in 
December 2015. For the purpose of this analysis, patients treated with canakinumab 
for conditions other than definite CAPS were excluded, as were patients without 
information of the presence or absence of any vaccination reactions. 
 
Statistical analysis 
Categorical variables were calculated as frequencies and percentages and 
continuous variables were calculated as means with standard deviations (SD) and 
 medians with interquartile ranges (IQRs). Mann-Whitney-U tests were applied for 
across group comparisons. Odds ratios and their corresponding 95% confidence 
intervals (CIs) were obtained using univariate logistic regression analysis taking the 
clustering of vaccine injections within one patient into account. All statistical analyses 
were performed with Stata/IC 13.1 (StataCorp, College Station, Texas, USA).  
 
RESULTS 
The β-CONFIDENT registry followed 285 patients, 68 of whom fulfilled the inclusion 
criteria (Figure 1). The 68 included patients received 159 vaccine injections and were 
followed in 14 centres in nine countries. The majority of patients (81%) had been 
vaccinated against influenza, 26% of patients had received a pneumococcal 
vaccination, 18% of patients had received vaccinations with tetanus and diphtheria 
antigens and 16% of patients had received at least one vaccine directed against 
other pathogens (Figure 1). During the observation period, 43 CAPS patients (63%) 
had received more than one vaccine injection. Due to the inclusion criteria of the β-
CONFIDENT registry, all patients were concomitantly treated with canakinumab at 
enrolment into the registry. The demographic and disease characteristics of the 
patients are provided in Table 1.  
Of the total of 159 vaccine injections administered to the 68 CAPS patients, there 
were 22 injections in 18 patients that elicited at least one vaccine reaction (Table 2). 
The majority of vaccine reactions (n=13) occurred in 12 patients receiving 
pneumococcal vaccines. Twelve of the 15 pneumococcal polysaccharide vaccine 
(PPV) injections (80%) elicited a vaccine reaction and none of the two patients who 
were administered a pneumococcal conjugate vaccine (PCV). In two pneumococcal 
vaccinations, one of which elicited a reaction, the exact vaccine type was unknown. 
The high frequency of pneumococcal vaccine reactions contrasted with that of 
reactions to other vaccine types; only 17% and 7% of the tetanus/diphtheria and 
influenza vaccinations elicited a vaccine reaction, respectively. The odds ratio to 
react to any of the pneumococcal vaccines compared to influenza vaccines was 31.0 
(95%CI 8-119) and compared to tetanus/diphtheria vaccines was 10.8 (95%CI 2-74). 
Considering only PPV reactions, the odds ratio compared to influenza vaccinations 
 was 57.1 (95%CI 13-252) and compared to tetanus/diphtheria vaccinations was 12.2 
(95%CI 1-102). 
The severity of the vaccine reactions, as assessed by the number and intensity of 
different inflammatory symptoms (fever, swelling, erythema, and pain) was also 
increased after PPV vaccination compared to other vaccines (Table 2). Fever was 
elicited by almost half of all PPV injections. All symptoms after pneumococcal 
vaccination were observed very rapidly, usually within hours. Unlike the symptoms 
observed after influenza, tetanus or diphtheria vaccination, which resolved rapidly, 
the symptoms related to PPV were much more prolonged and in some cases lasted 
more than three weeks.  
In two MWS patients, PPV exposure was also associated with symptoms attributable 
to CAPS reactivation. One patient developed meningitis and the C-reactive protein 
was reported to be elevated one day after PPV injection. The events resolved after a 
period of 10 to 18 days. 
During the entire observation period, there were a total of five patients experiencing 
vaccine related serious adverse events (SAEs). Four events were observed in MWS 
patients and one in a NOMID patient; all were observed after PPV injections. The 
SAEs required hospital treatment in three cases. In one patient, a hospital 
consultation was necessary due to fever and local inflammation one day after PPV. 
Hospitalisation was required in two patients, four days after PPV due to meningitis 
and cellulitis at the injected arm in one patient and seven days after PPV due to 
progressive cellulitis at the injected arm in another patient. A fourth patient also 
developed local inflammation immediately after the injection. Over the next three 
days, this patient worsened and developed a swollen, hot erythematous arm, as well 
as nausea, headache and fever. A fifth patient developed local inflammation and 
fever one day after the PPV injection. 
In all five patients, the vaccine related SAEs resolved after a period of 10-28 days. 
Two patients had been vaccinated twice with pneumococcal vaccine. One patient 
first received PCV followed by PPV two months later and did not experience any 
vaccine reactions. The second patient received two PPV vaccines 1.8 years apart. 
This patient experienced only pain at the first vaccination, but developed pain, fever, 
and erythema which lasted for 12 days after the second PPV injection.  
 Nine of the 12 patients who had reacted to pneumococcal vaccines had been 
previously (n=7) or subsequently (n=5) vaccinated with other vaccines (18 influenza 
vaccine injections and two vaccinations against tetanus/diphtheria). In these nine 
patients, none of the other vaccine injections had elicited a vaccine reaction. 
Comparing the pneumococcal vaccine reactions among the different CAPS 
phenotypes, patients with NOMID had a higher nominal proportion of different 
injection site symptoms than patients with MWS or FCAS and a higher incidence of 
fever (Table 3). Patients who reacted to pneumococcal vaccines also tended to be 
younger than those who did not react. The former also had a slightly shorter time 
since the last administration of canakinumab, but had received lower canakinumab 
doses (Table 4). There was also no association between the time from the last 
canakinumab administration, or the canakinumab dose and the number of reaction 
symptoms (p=0.57, p=0.17, respectively).  
Antibody titre measurements following vaccination were recorded in a total of four 
patients, all of whom had received PPV. In these four patients, PPV had resulted in 
titres considered to be protective. 
 
DISCUSSION 
This prospective observational study demonstrates that in CAPS patients, 
pneumococcal vaccines are associated with adverse events that are more frequent, 
more severe, and longer lasting than comparator vaccines such as tetanus, 
diphtheria and influenza. Pneumococcal vaccination was also associated with a high 
rate of serious events. The events associated in this study with pneumococcal 
vaccinations also appear more frequent and more intense than those previously 
reported after pneumococcal immunisation in healthy persons [10] and in patients 
with other rheumatic diseases [11]. Of note, there was a strikingly higher incidence of 
serious post pneumococcal vaccine reactions which also appeared more severe than 
those previously reported in healthy persons and in patients with other rheumatic 
diseases [10].  
Some cases in this study also suggested that pneumococcal vaccines can trigger 
systemic inflammation and even CAPS flares. Our early recognition of these findings 
 led us to publish information about six patients from the registry and an additional 
patient not treated with canakinumab [8]. The present study confirms, extends, and 
puts the findings from the previous case series into perspective. One hypothesis that 
could explain the adverse events following pneumococcal vaccination is that 
pneumococcal antigens contain TLR2 and TLR4-ligands which trigger the rapid onset 
and systemic symptoms in patients who are genetically prone to inflammasome 
overactivation, i.e. in CAPS patients [8]. The observation that patients with the more 
severe CAPS phenotype (NOMID) appeared to have more frequent and more severe 
events than CAPS patients with the less severe phenotype (FCAS), also supports a 
role of inflammasome hyperactivation in this adverse reaction. PPV commonly 
utilizes purified polysaccharides from 23 pneumococcal serotypes; immunity is 
induced primarily through stimulation of IgM secreting B-cells without the assistance 
of T cells. Since there is no immunoglobulin type switch, the PPV vaccine does not 
elicit IgA antibodies and mucosal immunity; immunisation is not life-long [12]. PCV 
contains capsular polysaccharides covalently bound to diphtheria toxoid, but employs 
antigens of fewer pneumococcal serotypes than PPV. In contrast to PPV, PCV elicits 
long lasting T-helper cell dependent immune responses, immunoglobulin type 
switching, mucosal immunity, and immunologic memory [12]. Interestingly, all of the 
adverse events described in this study after pneumococcal vaccinations were 
associated with PPV, though numbers are too small to warrant any conclusion about 
a potential difference between the two. Both vaccines however contain TLR2 and 4 
ligands and vaccine reactions to PCV have been also observed in a 24 year old 
woman with FCAS not followed in this registry (HMH unpublished observation) as 
well as another CAPS case [8], suggesting that the inflammatory reaction is not 
restricted to the PPV vaccine subtype.   
Moreover, familial Mediterranean fever is a condition associated with increased 
inflammasome activation [13]. The β-CONFIDENT registry also followed a boy with 
familial Mediterranean fever. This boy (not included in this analysis of the registry) 
was vaccinated with PPV at the age of 13. Within less than one day, the boy 
experienced severe pain and massive swelling at the injection site. These symptoms 
lasted for seven days. Further support for the permissive role of the inflammasome 
for the pneumococcal vaccine reactions stems from similar events reported in patient 
with Behçet’s disease [14], a condition also associated with aberrant inflammasome 
activation [13,15].  
 It is intriguing that not all patients receiving pneumococcal vaccines in the β-
CONFIDENT registry appear to have reacted to pneumococcal vaccines. We cannot 
fully rule out recall deficits or incomplete data capture as a possible explanation. On 
the other hand, canakinumab may be expected to mitigate symptoms by 
counteracting an enhanced IL-1 β activation. We however failed to identify a 
protective effect of canakinumab in our CAPS patients as there was no association 
between the presence or severity of the vaccine reactions with canakinumab dose or 
timing. Local vaccine reactions could however also be explained by insufficient 
canakinumab concentrations. The lack of a protective effect of canakinumab may 
however also result from the involvement of proinflammatory pathways other than IL-
1β, as the activated inflammasome can also activate preforms of IL-18, induce 
inflammatory cell death known as pyroptosis, and enhance eicosanoid production 
[13,14].  
The risk of adverse vaccine reactions must be clearly weighed against the risk of 
pneumococcal infections. Mice with dysfunctional NLRP3 signalling are more 
susceptible to pneumococcal pneumonia [4,14], providing an argument in favour of 
continued vaccination. In the absence of more robust data it is unclear if both types 
of pneumococcal vaccines elicit inflammatory symptoms to a similar degree. The 
authors tend to favour the 13-valent PCV over PPV in CAPS patients, also for the 
immunologic advantages of PCV discussed above. 
The NLRP3 inflammasome plays an important role in the generation of 
pneumococcal antibodies following vaccination and is also required for the effects of 
aluminium and other vaccine adjuvants raising the possibility of an impaired vaccine 
efficacy [15–17]. We did not detect an impaired antibody production in the few 
patients treated with canakinumab that had pneumococcal antibody titre 
measurements. Future research should consider systematic measurements of 
antibody titres and could also investigate if pneumococcal vaccine side effects could 
be mitigated by employing reduced antigen doses, or by concomitantly administering 
anti-inflammatory medications such as cyclooxygenase inhibitors and 
glucocorticosteroids [13,18].  
In conclusion, pneumococcal vaccines, unlike other vaccines, trigger severe local 
and systemic inflammation in CAPS. Clinicians must weigh potential benefits of 
pneumococcal immunisation against safety concerns. 
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Figure 1. Flow chart of patients included and excluded in the analysis 
* Five patients received more than one vaccine injection against different pathogens. 
  
 Table 1. Demographics and disease characteristics of cryopyrin-associated periodic syndromes patients at their first 
vaccination  
Vaccinea Influenza 
Tetanus + 
diphtheriab 
Pneumococcus Other  
Pneumococcal vaccine subtype -  - PCV PPV Unknown  - 
Patients who received a vaccination, n 55 12 2 14 2 11 
Age  
Mean years (SD) 36 (18) 24 (13) 31 (30) 41 (17) 31 (18) 26 (16) 
Median years (IQR) 37 (18-51) 23 (16-30) 31 (10-52) 47 (24-54) 31 (18-43) 25 (15-45) 
Patients <16 years, n (%) 9 (16) 3 (25) 1 (50) 1 (7) 0 (0) 4 (36) 
Female sex, n (%) 30 (55) 6 (50) 2 (100) 10 (71) 2 (100) 4 (36) 
CAPS symptom duration  
Mean years (SD) 30 (19) 19 (12) 30 (31) 36 (21) 25 (26) 22 (17) 
Median years (IQR) 32 (15-44) 16 (15-23) 30 (8-51) 40 (19-54) 25 (6-43) 15 (14-28) 
CAPS phenotype  
NOMID n (%) 4 (7) 0 (0) 1 (50) 2 (14) 0 (0) 1 (10) 
MWS n (%) 34 (62) 7 (58) 0 (0) 11 (79) 1 (50) 5 (45) 
FCAS n (%) 17 (31) 5 (42) 1 (50) 1 (7) 1 (50) 5 (45) 
Known NLRP3 mutation, n (%) 52 (95) 11 (92) 2 (100) 14 (100) 2 (100) 11 (100) 
  
aVaccines containing tetanus and diphtheria antigens: Tetanus/diphtheria (5 patients), Diphtheria/tetanus/pertussis (5 patients), 
Diphtheria/tetanus/pertussis/polio (1 patient), Diphtheria/tetanus/haemophilus influenzae type b (1 patient). bOther vaccines: hepatitis 
B (6 patients), hepatitis A (5 patients), typhoid, (3 patients), tick borne encephalitis (2 patients), polio (1 patient), mumps, measles, 
rubella (1 patient), human papillomavirus (1 patient), lyme disease (1 patient) and cholera (1 patient). FCAS: familial cold 
autoinflammatory syndrome; MWS: Muckle-Wells Syndrome; NLRP3: nucleotide-binding domain, leucine-rich family pyrin domain 
containing protein 3;  NOMID: neonatal onset multisystem inflammatory disease; PCV: pneumococcal conjugate vaccine; PPV: 
pneumococcal polysaccharide vaccine. 
  
Table 2. Canakinumab exposure of cryopyrin-associated periodic syndromes  patients and vaccination reactions according 
to the vaccine type  
Vaccine Influenza 
Tetanus + 
diphtheriaa 
Pneumococcus Otherb 
Pneumococcal vaccine subtype - -  PCV PPV Unknown   
Injections, n 107 12 2 15 2 21 
Time since last canakinumab       
Mean days (SD) 56 (138) 88 (123) 10 (7) 22 (18) 37 (28) 99 (140) 
Median days (IQR) 36 (17-50) 38 (31-59) 10 (6-14) 22 (2-41) 37 (17-57) 42 (30-79) 
≤30 days; n (%) 44 (41) 2 (17) 2 (100) 10 (67) 1 (50) 6 (29) 
Last canakinumab dose       
Mean mg/kg (SD) 2.6 (1.2) 3.1 (1.2) 7.9 (8.3) 2.7 (1.3) 1.8 (0.1) 3.2 (1.7)  
Median mg/kg (IQR) 2.1 (1.8-2.7) 2.7 (2.3-4.1) 7.9 (2.0-13.8) 2.2 (1.9-2.5) 1.8 (1.7-1.8) 2.4 (2.1-4.4) 
Patients receiving ≤2 mg/kg, n (%) 43 (41) 1 (8) 0 (0) 4 (27) 2 (100) 3 (14) 
Injections eliciting any vaccine reaction, n (%) 7 (7) 2 (17) 0 (0) 12 (80) 1 (50) 0 (0) 
Injections eliciting no reaction, n (%) 100 (93) 10 (83) 2 (100) 3 (20) 1 (50) 21 (100) 
Injections with one reaction featurec, n (%) 2 (2) 0 (0) 0 (0) 1 (7) 1 (50) 0 (0) 
Injections with two reaction feature, n (%) 3 (3) 0 (0) 0 (0) 1 (7) 0 (0) 0 (0) 
Injections with three reaction features, n (%) 2 (2) 2 (17) 0 (0) 4 (26) 0 (0) 0 (0) 
Injections with four reaction features, n (%) 0 (0) 0 (0) 0 (0) 6 (40) 0 (0) 0 (0) 
 Fever, n injections (%) 2 (2) 0 (0) 0 (0) 7 (47) 0 (0) 0 (0) 
Time to fever onset, days, median (IQR) 2 (1-3) na na  1 (1-1) na  na  
Duration of fever, days, median (IQR) 0.5 (0-1) na  na  17 (9.5-22) na  na  
Fever maximum, °C, median (IQR) 38.2 na   na 39.3 (39.0-39.6) na na 
Swelling, n injections (%) 4 (4) 2 (17) 0 (0) 9 (60) 0 (0) 0 (0) 
Time to swelling onset, days, median (IQR) 0 (0-1) 1 na  1 (0-1) na  na  
Swelling duration, days, median (IQR) 2 (1-7) unknown na  8 (4-22) na  na  
Erythema, n injections (%) 4 (4) 2 (17) 0 (0) 11 (73) 1 (50) 0 (0) 
Time to erythema onset, days, median (IQR) 0 (0-0) 0.5 (0-1) na  1 (0-3) 0 na  
Erythema duration, days, median (IQR) 1 (1-9) unknown na  9.5 (5.5-17) unknown na  
Pain, n injections (%) 3 (3) 2 (17) 0 (0) 12 (80) 0 (0) 0 (0) 
Time to pain onset, days, median (IQR) 1 1 na  0 (0-3) na  na  
Pain duration, days, median (IQR) 7 unknown na  9 (4-22) na  na  
SAE, n patients (%) 0 (0) 0 (0) 0 (0) 5 (33.3) 0 (0) 0 (0) 
Unless otherwise stated, the numbers and percentages presented are based on vaccine injections, not patients. aVaccines containing tetanus and 
diphtheria antigens: Tetanus/diphtheria (5 patients), Diphtheria/tetanus/pertussis (5 patients), Diphtheria/tetanus/pertussis/polio (1 patient), 
Diphtheria/tetanus/haemophilus influenzae type b (1 patient). bOther vaccines: hepatitis B (6 patients), hepatitis A (5 patients), typhoid, (3 patients), 
tick borne encephalitis (2 patients), polio (1 patient), mumps, measles, rubella (1 patient), human papillomavirus (1 patient), lyme disease (1 
patient) and cholera (1 patient). cVaccine reaction features systematically asked for in the registry consist of fever, swelling, erythema and pain. 
FCAS: familial cold autoinflammatory syndrome; MWS: Muckle-Wells Syndrome; NOMID: Neonatal onset multisystem inflammatory disease; na: 
not applicable; PCV: Pneumococcal conjugate vaccine; PPV: Pneumococcal polysaccharide vaccine; SAE: serious adverse event.   
 
  
Table 3. Vaccine reactions after pneumococcal vaccine injections, stratified by cryopyrin-associated periodic syndromes 
phenotype 
 NOMID MWS FCAS 
Pneumococcal vaccinations, n 3 13 3 
Injections eliciting a vaccine reaction, n (%) 2 (67) 10 (77) 1 (33) 
Injections eliciting no reaction, n (%) 1 (33) 3 (23) 2 (67) 
Injections with one reaction feature, n (%) 0 (0) 1 (8) 1 (30) 
Injections with two reaction feature, n (%) 0 (0) 1 (8) 0 (0) 
Injections with three reaction features, n (%) 0 (0) 4 (31) 0 (0) 
Injections with four reaction features, n (%) 2 (67) 4 (30) 0 (0) 
Fever, n (%) 2 (67) 5 (38) 0 (0) 
Time to fever onset, days, median (IQR) unknown 1 (1-1) na 
Duration of fever, days, median (IQR) unknown 17 (10-22) na 
Swelling, n (%) 2 (67) 7 (54) 0 (0) 
Time to swelling onset, days, median (IQR) 1 (1-1) 1 (0-1) na  
Duration of swelling, days, median (IQR) unknown  8 (4-22) na  
Erythema, n (%) 2 (67) 9 (69) 1 (33) 
Time to erythema onset, days, median (IQR) 0.5 (0-1) 1 (0-1) 0 (0) 
Duration of erythema, days, median (IQR) unknown 10 (6-17) unknown 
Pain, n (%) 2 (67) 10 (77) 0 (0) 
 Time to pain onset, days, median (IQR) 0 (0-0) 0 (0-1) na 
Duration of pain; median days (IQR) unknown 9 (6-17) na 
SAE; n patients (%) 1 (33) 4 (31) 0 (0) 
Unless otherwise stated, the numbers and percentages presented are based on vaccine injections, not patients. FCAS: familial cold 
autoinflammatory syndrome; MWS: Muckle-Wells syndrome; na: not applicable; NOMID: neonatal onset multisystem inflammatory 
disease; SAE: serious adverse event. 
  
Table 4. Comparison of demographic and treatment characteristics of cryopyrin-associated periodic syndromes  patients 
recieving pneumococcal vaccine injections 
 No reaction Any reaction 
Pneumococcal vaccine injections, n (%) 6 13 
Age   
Mean years (SD) 46 (19) 36 (16) 
Median years (IQR) 52 (43-54) 42 (20-50) 
Patients <16 years, n (%) 1 (17) 1 (8) 
Female sex, n vaccine injections (%) 6 (100) 8 (62) 
CAPS symptom duration   
Mean years (SD) 45 (20) 29 (19) 
Median years (IQR) 52 (43-54) 26 (15-42) 
NLRP3 mutation, n (%) 6 (100) 13 (100) 
Time since last canakinumab   
Mean days (SD) 29 (24) 19 (16) 
Median days (IQR) 26 (6-56) 18 (2-37) 
≤30 days, n (%) 3 (50) 10 (77) 
>30 days, n (%) 3 (50) 3 (23) 
Last canakinumab dose   
Mean mg/kg (SD) 4.0 (4.8) 2.7 (1.4) 
 Median mg/kg (IQR) 2.0 (2.0-2.3) 2.2 (1.9-2.5) 
Patients receiving ≤2 mg/kg, n (%) 1 (17) 5 (38) 
Patients receiving >2 mg/kg, n (%) 3 (83) 8 (62) 
The numbers and percentages presented are based on vaccine injections, not patients. NLRP3: nucleotide-binding domain, leucine-
rich family pyrin domain containing 3. 
